RecruitingNCT06574373
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Studying Intraductal papillary mucinous carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Principal Investigator
- Carmine Carbone, PhDFondazione Policlinico Universitario Agostino Gemelli IRCCS
- Intervention
- Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention(other)
- Enrollment
- 3600 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- Fondazione Policlinico Gemelli, Roma, Italy
- IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
Collaborators
Azienda Ospedaliera Universitaria Integrata Verona · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale · University of Messina
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06574373 on ClinicalTrials.govOther trials for Intraductal papillary mucinous carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07216521Intent of Surgery for IPMNNYU Langone Health
- RECRUITINGNCT07117045Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic CancerChanghai Hospital
- ACTIVE NOT RECRUITINGNANCT06712797Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception CenterH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06694792Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) ConsortiumIRCCS San Raffaele
- ENROLLING BY INVITATIONNCT06276764The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)Adenocyte, LLC
- RECRUITINGNCT06638866AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening CohortChanghai Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06519097Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)H. Lee Moffitt Cancer Center and Research Institute
- ENROLLING BY INVITATIONNCT06283576Pancreatic Cancer Initial Detection Via Liquid BiopsyKarolinska University Hospital
See all trials for Intraductal papillary mucinous carcinoma of pancreas →